Search results
Results From The WOW.Com Content Network
Shares of Merck (NYSE: MRK) were trading lower on Tuesday. The company's stock had lost 10.1% as of 2 p.m. ET, but was down as much as 12.5% earlier in the day. The drop comes as the S&P 500 ...
Further, even beyond Keytruda's upcoming loss of patent exclusivity in the U.S., Merck could face stiff competition for its cash cow from at least two cancer drugs in development. Merck's Keytruda ...
Merck & Co. traces its origins to its former German parent company Merck Group, which was established by the Merck family in 1668 when Friedrich Jacob Merck purchased a drug store in Darmstadt. [ 27 ] [ 28 ] In 1827, Merck Group evolved from a pharmacy to a drug manufacturer company with the commercial manufacture of morphine . [ 29 ]
Even with that growth, the stock still trades at a fairly modest valuation. Its stock price is up 5.3% this year, compared with 16% growth for the S&P 500. Why isn't Merck's stock doing better in ...
Sigma-Aldrich was created in 1975 by the merger of Sigma Chemical Company and Aldrich Chemical Company. It grew through various acquisitions until it had over 9,600 employees and was listed on the Fortune 1000. The company has two United States headquarters, in St. Louis and Burlington, MA and has operations in approximately 40 countries. [7]
There is plenty to like about Merck (NYSE: MRK). It is one of the largest pharmaceutical companies and the owner of the world's current best-selling drug, cancer medicine Keytruda. Merck generates ...
In 1891, Georg(e) Merck established himself in the United States and set up Merck & Co. with Theodore Weicker in New York. Merck & Co. was confiscated following the First World War and set up as an independent company in the United States. [14] [15] Today, the US company, which operates as Merck Sharp and Dohme (MSD) outside the U.S. and Canada ...
The next few years might get bumpy for the pharmaceutical giant, but the longer term looks better.